幕下动静脉畸形相关血流相关性动脉瘤的基于位置的血管内治疗:25例37个动脉瘤分析
该回顾性研究分析了2020年1月至2024年6月间25例幕下动静脉畸形合并血流相关性动脉瘤(FRA)患者的血管内治疗经验。治疗根据FRA位置个体化:近端FRA采用弹簧圈栓塞以保留远端血流,远端FRA使用液体栓塞剂并常需牺牲载瘤动脉。平均随访22.1个月,24例(96.0%)获得良好结局(mRS≤2),3例(12.0%)发生临床显著并发症。
要点
- 近端FRA以弹簧圈栓塞为主(21/22,95.5%),以保留远端灌注。
- 远端FRA以液体栓塞剂经供血动脉牺牲治疗为主(14/15,93.3%)。
- 平均随访22.1个月,96.0%患者获得良好结局(mRS≤2)。
核心结论
- 幕下AVM相关FRA的自然史不可预测,除非AVM完全闭塞,否则推荐积极治疗。
- 血管内治疗是幕下AVM相关FRA安全有效的首选治疗方法。
研究设计与样本
- 回顾性分析2020年1月至2024年6月连续25例破裂或症状性FRA患者。
- 治疗根据FRA位置 tailored:近端FRA弹簧圈栓塞,远端FRA液体栓塞剂。
- 系统回顾临床结局、影像学表现和治疗方式。
主要发现
- 出血是最常见就诊症状(19/25,76.0%),其中FRA破裂15例,AVM巢出血4例。
- 共治疗37个FRA,近端动脉瘤多采用弹簧圈栓塞(21/22,95.5%),远端FRA多采用液体栓塞剂(14/15,93.3%)。
- 3例(12.0%)发生临床显著并发症,包括2例缺血事件和1例脑积水。
- 平均随访22.1个月,24例(96.0%)获得良好结局(mRS≤2)。
- 1例患者在治疗后3年因未治疗FRA增大破裂再出血。
关键数值与推荐
- 近端FRA弹簧圈栓塞比例21/22(95.5%)。
- 远端FRA液体栓塞剂治疗比例14/15(93.3%)。
- 临床显著并发症发生率3/25(12.0%)。
- 良好结局(mRS≤2)比例24/25(96.0%),平均随访22.1个月。
临床怎么用
- 对幕下AVM相关FRA应根据位置选择血管内治疗策略:近端栓塞保留远端血流,远端可牺牲供血动脉。
- 除非AVM完全闭塞,否则应对FRA积极治疗以降低再出血风险。
- 治疗后需长期随访,警惕未治疗FRA增大破裂。
局限性
- 回顾性研究设计。
- 样本量较小(25例患者,37个动脉瘤)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The management of flow-related aneurysms (FRAs) associated with infratentorial arteriovenous malformations (AVMs) remains challenging and controversial. In this study, we present our clinical experience with endovascular treatment of these complex lesions. METHODS: We retrospectively analyzed 25 consecutive patients with ruptured or symptomatic FRAs treated between January 2020 and June 2024. Treatment was tailored to FRA location: proximal FRAs underwent coil embolization to preserve distal flow, while distal FRAs received liquid embolics, often requiring parent artery sacrifice. Clinical outcomes, radiological findings, and treatment approaches were systematically reviewed. RESULTS: Hemorrhage was the most common presenting symptom (19/25, 76.0%), with FRA rupture accounting for 15 cases and AVM nidus bleeding for the remaining 4. Endovascular treatment was performed for 37 FRAs, with proximal aneurysms predominantly managed by coiling (21/22, 95.5%) to preserve distal perfusion, while distal FRAs were primarily treated with liquid embolics (14/15, 93.3%) via feeder sacrifice. Three (12.0%) clinically significant complications occurred, including 2 ischemic events and one case of hydrocephalus. At a mean follow-up of 22.1 months, 24 patients (96.0%) achieved favorable outcomes (modified Rankin Scale ≤2). One patient experienced rebleeding due to enlargement and rupture of an untreated FRA 3 years post-treatment. CONCLUSIONS: The natural history of FRAs associated with AVMs remains unpredictable. We recommend aggressive treatment in all cases unless complete AVM occlusion is achieved. Endovascular treatment represents a safe and effective primary therapeutic approach for infratentorial AVM-associated FRAs.
引用
- Liu XL, Jiang RH, Zhao LB, et al. Flow-Related Aneurysms in Infratentorial Arteriovenous Malformations: Location-Based Endovascular Treatment of 37 Aneurysms in 25 Cases. World Neurosurg. 2025. PMID: 40782911. doi:10.1016/j.wneu.2025.124368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。